semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cervical Neoplasia Age > 18 Women with premalignant cervical lesions who are candidates for conization (group A) Women with a normal cervix who are candidates for hysterectomy (group B) Women with newly diagnosed cervical cancer  For group A and B women that had conization in the past
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 20.0-65.0,  Bladder Dysfunction Women with cervical cancer stage IB IIA underwent standard type III radical hysterectomy, both open and laparoscopic approach Patient aged 20 years Patient able to give free and informed consent and who agrees to participate be signing the consent form  Patient who had an allergic reaction to bethanechol chloride Patient who had neurogenic bladder
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cervix Uteri Dilation Subjects, females, 18 years of age or older Subjects undergoing any process that requires dilation (intrauterine procedures) Subjects willing to sign informed consent form  Subjects younger than 18 years of age Subject with sex transmitted diseases, or with infectious diseases (HIV, HCV) Subjects unwilling to sign the informed consent form
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Cervical Cancer Women with histological verified CIN 2 or CIN 3 Women with histological verified cervical cancer  Women with mild cervical lesions
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Giant Cell Tumors Written informed consent for participation in the study (ICF) Patients with diffuse TGCT (diagnosed histologically) confirmed naïve or recurrent case  None
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Stress Disorders, Post-Traumatic Intimate Partner Violence Alcohol-Related Disorders Female Veterans Lifetime history of ST with at least one risk factor: heavy drinking within the past 3 months, screen positive for current PTSD or for IPV within last 12 months Age 18-65 Seeking treatment through the Women's Primary Care Clinics at the Central Texas VA Healthcare System Ability to understand study procedures in English Not actively in suicidal or homicidal crisis warranting imminent hospitalization
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Staphylococcal Infections Infections after fracture fixation or prosthetic joint surgery Affected bone or joint: Long bones of the lower and upper extremity Bacterial growth of S. aureus at the site of interest Written consent Age: 18 and older  no prove of bacterial growth at site of interest missing consent infections involving external fixation pins, infections without any implanted hardware
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hematologic Malignancy Histologically confirmed hematologic malignancy Undergoing evaluation at the BMTU at the Puget Sound VA Planning or receiving an autologous or allogeneic HCT  • Patients who for any reason elect not to participate
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cancer Histological or cytological confirmation of cancer Patient being considered for participation in an experimental therapeutic trials Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow up schedule (such conditions should be discussed with the patient before registration in the study)  Age below 18 years old Patient not physically and mentally able to give informed consent
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 25.0-65.0,  Cervical Cancer Screening Self-identify as lesbian, bisexual, or queer woman Assigned female sex at birth English speaking ages 25-65 years report not having had a pap smear in the last three years (per guidelines) if age 30 or over, report not having a pap smear/HPV co-test within the past 5 years (per guidelines)  report having had a hysterectomy report having history of cervical cancer unable to consent Pregnant women Prisoners
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Cervical Cancer Urinary Retention FIGO stage IB ASA score 0-2  Radiotherapy or chemotherapy before surgeries ASA score > 2 With abnormal urinary dynamics before surgeries
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 21.0-999.0,  Method of Tubal Ligation at the Time of Cesarean Section Subjects must have planned cesarean delivery and desire sterilization Subjects must be able to read and provide written informed consent Subjects must be English or Spanish speaking  Subjects with known hereditary cancer syndromes Subjects with a history of prior tubal surgery Subjects with a placenta accreta Subjects undergoing trial of labor after cesarean delivery
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cystic Fibrosis Female with Cystic fibrosis Age 18 years or older transplanted or non-transplanted Accepting the principle of a gynecological consultation and the principle of follow-up every 6 months in case of abnormal smear or positive HPV test Patient covered by health insurance  Age under 18 Refusal to participate in the study Patient under tutorship / curatorship
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 25.0-64.0,  Cervical Intraepithelial Neoplasia Grade 2/3 Women with previous abnormal cervical cancer screening test results Women between the ages of 25 and 64  Hysterectomised women Women with known pregnancy Non-consenting women Women that are not able to understand and to sign the informed consent
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 40.0-55.0,  Cervical Cancer Being literate Have not received any training on cervical cancer before  Being pregnant or postpartum quarterly Have already been diagnosed with any cancer Not having sexual experience Having undergone hysterectomy operation
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  ER-positive Her2-negative Early Breast Cancer Woman, Age ≥ 18 years; 2. Performance status 0 or 1 (according to World Health Organization criteria); 3. Patient with newly diagnosed, unilateral, localized, histologically confirmed, invasive breast cancer; Note: Multicentric/multifocal tumors are allowed provided a maximum of 3 lesions are present, and all are ER > 10% or Allred ≥ 4, Her2-negative (genomic test will be performed on the lesion considered the most pertinent by the multidisciplinary team) 4. Fully operated breast cancer including complete resection of breast tumor and adequate axillary surgery; 5. Available surgical material (formalin-fixed, paraffin-embedded) for genomic test evaluation; 6. ER-positive by immuno-histochemical (>10% cells stained or Allred Score≥4); 7. HER2-negative by IHC (score 0 or 1+) and/or fluorescence in situ hybridization/silver in situ hybridization/chemiluminescent in situ hybridization ; 8. Uncertainty regarding the toxicity/benefit of adjuvant chemotherapy, outlined in the following situations Grade 1: pT3 or 1-3 node positive Grade 2: pT1 pN0 but high proliferation (Ki67 >20%) or lympho-vascular emboli, or 1-3 node positive Grade 2 : pT2 pN0 Grade 3: pT1 pN0 9. Adequate renal, hepatic, cardiac and hematopoietic functions for a chemotherapy administration; 10. Willingness and ability to comply with scheduled visits as well as with test results and chemotherapy decision according to the latest; 11. Signed informed consent and Health insurance coverage  Non operable, bilateral, locally advanced, T4 or metastatic breast cancer; 2. HER2 Overexpression, as assessed by 3+ IHC or FISH/SISH/CISH amplification; 3. Diagnosis of any previous malignancy within the last 5 years, except for adequately treated basal cell carcinoma, or squamous cell skin carcinoma, or in situ cervical carcinoma; 4. Any previous systemic or locoregional treatment for the present breast cancer; 5. Documented inherited predisposition with BRCA1/2 or TP53 mutation; 6. Previous hormone replacement therapy (HRT) stopped less than 2 weeks before surgery; 7. Previous treatment for the present breast cancer; 8. Person unable to give informed consent
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 40.0-65.0,  Breast Cancer Cervical Cancer self-identify as Muslim female residence in a NYC borough self-report as having received a mammogram more than two years ago and are age 40-74 years self-report having received a Pap test more than three years ago and are age 40-65 years  Report a past or current diagnosis of breast or cervical cancer Report having had a hysterectomy Report having had breast reconstructive surgery
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Stage 0 Bladder Urothelial Carcinoma Stage 0is Bladder Urothelial Carcinoma Stage I Bladder Urothelial Carcinoma Patients must have histologically proven Ta, carcinoma in situ (CIS) or T1 stage urothelial cell carcinoma of the bladder within 90 days of registration Patients must have had all grossly visible papillary tumors removed within 30 days prior to registration or cystoscopy confirming no grossly visible papillary tumors within 30 days prior to registration Patients with T1 disease must have cross-sectional imaging of abdomen/pelvis demonstrating no evidence of metastatic disease (magnetic resonance imaging [MRI] or computed tomography [CT] scan) within 90 days prior to registration; patients with T1 disease must have re-resection confirming =< T1 disease within 90 days prior to registration Patients must have high-grade bladder cancer as defined by 2004 World Health Organization (WHO)/International Society of Urological Pathology (ISUP) classification Patients must not have pure squamous cell carcinoma or adenocarcinoma Patients' disease must not have micropapillary components Patients must have no evidence of upper tract (renal pelvis or ureters) cancer confirmed by one of the following tests performed within 90 days prior to registration: CT urogram, intravenous pyelogram, magnetic resonance (MR) urogram, or retrograde pyelograms Patients must not have nodal involvement or metastatic disease No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for five years; patients with localized prostate cancer who are being followed by an active surveillance program are also eligible Patients must have a Zubrod performance status of 0-2
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Stage IA Non-Small Cell Lung Carcinoma Stage IB Non-Small Cell Lung Carcinoma Stage IIA Non-Small Cell Lung Carcinoma Stage IIB Non-Small Cell Lung Carcinoma Biopsy proven non-small cell lung cancer Minimum tumor dimension >= 1 cm (preferably >= 2 cm) No clinical evidence of nodal disease (N1-N3) as assessed by CT and/or positron emission tomography (PET)/CT Zubrod performance status 0-2 Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following Has not undergone a hysterectomy or bilateral oophorectomy; or Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months) No prior radiation to the same area No concurrent chemotherapy  Patients with tumors < 1 cm Patients with nodal disease or distant metastatic disease Patients may not be receiving any other investigational agents Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements Patients must not be pregnant Patients with allergies to iodinated contrast not amenable to pre-medication Patients who are not able to lie supine with arms raised, and cooperate with breathholding instructions
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Cystic Fibrosis Male or female subjects with a confirmed diagnosis of CF defined as a sweat chloride value ≥60 mmol/L by quantitative pilocarpine iontophoresis or two CF-causing mutations,documented in the subject's medical record or confirmed at screening Age 18 and above on the date of informed consent Weight ≥40 kg Homozygous for the F508del-CFTR mutation. Genotyping to be confirmed at screening Ability to perform a valid, reproducible spirometry test with demonstration of a forced expiratory volume in 1 sec (FEV1) >40% of predicted normal for age, sex and height Screening laboratory tests with no clinically significant abnormalities that would interfere with the study assessments (as judged by the Investigator) Subjects who are sexually active must agree to follow the study's contraception requirements  An acute upper or lower respiratory tract infection, pulmonary exacerbation, or changes in therapy for pulmonary disease within 4 weeks prior to Day 1 Major complications of lung disease (including massive hemoptysis, pneumothorax, or pleural effusion) within 8 weeks prior to screening Impaired renal function or known portal hypertension History of prolonged QT and/or QTcF (Fridericia's correction) interval (>450 msec) or QTcF >450 msec at Screening History of solid organ or hematological transplantation History of alcohol abuse or drug addiction (including cannabis, cocaine and opiates) during the past year, (as judged by the Investigator) Use of ivacaftor or lumacaftor, within 4 weeks of Day 1 Any change (initiation, change in type of drug, dose modification, schedule modification, interruption, discontinuation, or re-initiation) in a chronic treatment/prophylaxis regimen for CF or for CF-related conditions within 4 weeks prior to Day 1 Ongoing immunosuppressive therapy (including systemic corticosteroids) Hemoglobin <10 g/dL
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Malignant Neoplasm of Cervix, Endometrium and Ovary Resectable (ovarian, endometrial, cervical) cancers. 2. Anaesthetically fit (ASA 1 and 2). 3. Abdominal pannus below symphysis pubis  Non resectable gynecologic cancer. 2. Unfit patients. 3. Patients who refuse to share in the trial
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 25.0-65.0,  Uterine Cervical Neoplasms Women between 25 and 65 years old Met within Doctors of the World programs  History of total hysterectomy (= ablation of uterus and cervix) Never had sexual intercourse Last pap smear test made during the three last years (ou first pap smear test during the last year)